SCHEMBL31269194

SCHEMBL31269194

CC1(Oc2ncnc3c2nc(-c2ccc(CC(N)=O)cc2Cl)n3Cc2cccc(C#N)c2)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 1/20 0.36
▸ GPR119 Q8TDV5 3/20 0.35
▸ KLKB1 P03952 1/20 0.35
▸ KLK1 P06870 1/20 0.35
▸ CCR2 P41597 1/20 0.34
▸ ADRA1D P25100 1/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ HCRTR1 O43613 1/20 0.34
▸ HCRTR2 O43614 1/20 0.34
▸ ROCK2 O75116 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ YTHDC1 Q96MU7 1/20 0.33
▸ ACACB O00763 1/20 0.33
▸ PDCD1 Q15116 2/20 0.33
▸ CD274 Q9NZQ7 2/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ RIPK1 Q13546 1/20 0.33
▸ TDP2 O95551 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33
▸ DGAT1 O75907 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31269049 0.93 GPR119 (0.37) GPR119KLKB1KLK1PIK3CDHCRTR1
SCHEMBL31269294 0.91 TLR7 (0.35) TLR7GPR119PIK3CDPDCD1CD274
SCHEMBL31269133 0.90 PLA2G2A (0.38) TLR7PIK3CDCNR2DGAT1
SCHEMBL31268878 0.90 PIK3CD (0.36) ADRA1DPIK3CDCNR2DGAT1
SCHEMBL31269290 0.90 PIK3CD (0.37) PIK3CDROCK2CNR2DGAT1
SCHEMBL31268852 0.89 PIK3CD (0.36) PIK3CDHCRTR1HCRTR2ACACBDGAT1
SCHEMBL31269283 0.89 PIK3CD (0.38) PIK3CDCNR2DGAT1
SCHEMBL31269462 0.89 PDE4A (0.36) GPR119PIK3CDDGAT1
SCHEMBL31268757 0.88 PLA2G2A (0.38) CCR2ADRA1D
SCHEMBL31268911 0.88 GPR119 (0.36) GPR119PIK3CDHCRTR1HCRTR2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback